Navigation Links
Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic
Date:9/18/2007

cer. "Most importantly, we have demonstrated that a single treatment with our CCR5-specific ZFNs generates a population of HIV-resistant T-cells similar to the situation in individuals carrying the natural CCR5-delta32 mutation. We have shown that these ZFN-modified cells are made permanently resistant to HIV. Furthermore, the cells selectively survive and expand in an animal after HIV infection providing a reservoir of healthy and uninfectable immune cells. In a patient, such cells could be available to fight both opportunistic infections and HIV itself. In addition, we have reported on the successful ZFN-modification of clinical-scale quantities of human CD4 T-cells. The modified cells exhibited the expected properties of normal CD4 T-cells minus a functional CCR5 receptor. This demonstrates that ZFN-modified human CD4 T-cells can be produced in the quantities required for the translation of this program into the clinic which is our immediate goal for this ZFP Therapeutic."

Several major pharmaceutical companies have initiated programs to develop small molecule or antibody approaches to block the binding of HIV to CCR5. However, a small molecule or antibody approach requires the constant presence of a sufficiently high concentration of drug to block therapeutically relevant numbers of the CCR5 protein, which is present in thousands of copies on the surface of each T-cell and other tissues in the body. One such drug was recently approved by the US Food and Drug Administration with a "black box" warning, the strongest for prescription drugs, concerning the risk of liver toxicity and the possibility of heart attacks.

Sangamo's ZFN technology represents a means of potentially circumventing these limitations or risks by specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs. This results in permanent modification of the CCR5 protein so that HIV cannot enter and infect the cells. This appro
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... Earle Martin , Chief ... that Ellen Teplitzky, an experienced attorney specializing in ... industry, has joined the firm as Director of ... practice. NDA Partners provides legal services, including ... to top law firms and their clients in ...
(Date:10/19/2014)... Oct. 19, 2014 NextCODE Health, which enables clinicians ... in real time, today announced the launch of its new ... , at the American Society of Human Genetics (ASHG) annual ... more, sign up and apply for free beta access, visit ... and benefits can be viewed here . ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and ... and Forecast (2011 - 2016)," analyzes the chocolate ... the major market drivers, restraints, and opportunities for the ... The global chocolate market is expected to grow from ... an estimated CAGR of 2.7% from 2011 to 2016. ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... ... capabilities for Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference ... Convention Center. , ... Philadelphia, PA (PRWEB) June 1, 2009 -- Genedata , a leading provider of ...
... , - Results Presented at American Society of Clinical ... Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in ... 1 Mersana Therapeutics presented preliminary results of a ... XMT-1001, in a poster session at the 2009 Annual ...
... Webinar on June 9 to discuss the prevalence and prevention ... www.connecttoprotect.com - , , BETHESDA, ... (AGA) Institute and Horizon Therapeutics, Inc. today launched Connect ... gastrointestinal (GI) risks associated with the use of non-steroidal anti-inflammatory ...
Cached Biology Technology:Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 2Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors 3AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 2AGA Institute and Horizon Therapeutics Launch 'Connect to Protect' Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 3
(Date:10/15/2014)... The German Gauß-Allianz has admitted Johannes Gutenberg University ... the Rhineland-Palatinate science hub continues to maintain a ... computing. , "The acceptance of Johannes Gutenberg ... Gauß-Allianz is a milestone in the national and ... support. The state of Rhineland-Palatinate can be proud ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ("NXT-ID" or ... commerce market releases photos and video of the recent opening bell ... th . Gino Pereira , CEO of ... Mr. Chad A. Verdi rang the bell.  ... and employees "for their work and dedication in bringing the world,s ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... gene may be an early step in the development of ... this inactivation may ultimately be useful in risk assessment for ... 21 issue of the Journal of the National Cancer ... cells with a "field defect", cells that appear normal but ...
... Human Genome Research Institute (NHGRI), one of the National ... Sequencing Research Network will target 13 more organisms as ... that will expand biological knowledge and improve human health. ... (NACHGR), which is a federally chartered committee that advises ...
... Nanostructured micro-devices may be mass produced at a ... shapes and compositions than ever before, for dramatic ... biologically produced structures. These entirely new biologically-enabled approaches ... International Journal of Applied Ceramic Technology, published on ...
Cached Biology News:Change in gene may be underlying molecular defect in some colorectal cancers 2Possible treatment found for 'chemobrain' 2Possible treatment found for 'chemobrain' 3Possible treatment found for 'chemobrain' 4Possible treatment found for 'chemobrain' 5